1 INDICATIONS AND USAGE Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent .
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % is a combination of fluorescein sodium , a disclosing agent and benoxinate hydrochloride , a local ester anesthetic indicated for procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic .
( 1 ) 2 DOSAGE AND ADMINISTRATION Instill 1 to 2 drops topically in the eye as needed .
Instill 1 to 2 drops topically in the eye as needed to achieve adequate anesthesia .
( 2 ) 3 DOSAGE FORMS AND STRENGTHS Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % is a yellow to orange - red ophthalmic solution containing fluorescein sodium 2 . 6 mg / mL ( 0 . 3 % ) and benoxinate hydrochloride 4 . 4 mg / mL ( 0 . 4 % ) .
Ophthalmic solution containing fluorescein sodium 2 . 6 mg / mL ( 0 . 3 % ) and benoxinate hydrochloride 4 . 4 mg / mL ( 0 . 4 % ) .
( 3 ) 4 CONTRAINDICATIONS Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % is contraindicated in patients with known hypersensitivity to any component of this product .
Known hypersensitivity to any component of this product .
( 4 ) 5 WARNINGS AND PRECAUTIONS • • Corneal Toxicity : Prolonged use or abuse may lead to corneal epithelial toxicity and manifest as epithelial defects which may progress to permanent corneal damage .
( 5 . 1 ) • • Corneal Injury : Patients should not touch the eye for approximately 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye .
( 5 . 2 ) 5 . 1 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage with accompanying visual loss .
5 . 2 Corneal Injury Due to Insensitivity Patients should not touch the eye for approximately 20 minutes after using this anesthetic as accidental injuries can occur due to insensitivity of the eye .
6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling : • • Corneal Toxicity [ see Warnings and Precautions ( 5 . 1 ) ] • • Corneal Injury Due to Insensitivity [ see Warnings and Precautions ( 5 . 2 ) ] The following adverse reactions have been identified following use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % : ocular hyperemia , burning , stinging , eye irritation , blurred vision and punctate keratitis .
Because these reactions are reported voluntarily from a population of uncertain size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .
The most common ocular adverse events are : stinging , burning and conjunctival redness .
( 6 ) To report SUSPECTED ADVERSE REACTIONS , contact Bausch & Lomb Incorporated at 1 - 800 - 553 - 5340 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch .
8 USE IN SPECIFIC POPULATIONS 8 . 1 Pregnancy Risk Summary There are no available data on the use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % in pregnant women to inform any drug associated risk .
Adequate animal reproduction studies have not been conducted with fluorescein sodium and / or benoxinate hydrochloride .
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % should be given to a pregnant woman only if clearly needed .
8 . 2 Lactation Risk Summary There are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % , the effects on the breastfed infant , or the effects on milk production .
The developmental and health benefits of breastfeeding should be considered , along with the mother ’ s clinical need for Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % , and any potential adverse effects on the breastfed infant from Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % .
8 . 4 Pediatric Use The safety and effectiveness of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % have been established for pediatric patients .
Use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % is supported in pediatric patients by evidence from adequate and well controlled studies .
8 . 5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients .
11 DESCRIPTION Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % is a sterile solution containing a disclosing agent in combination with a short - acting ester anesthetic for topical ophthalmic use .
Fluorescein sodium is represented by the following structural formula : [ MULTIMEDIA ] Chemical Name : 3 ’ , 6 ’ Dihydroxy - 3 H - spiro [ isobenzofuran - 1 , 9 - xanthen ] - 3 - one disodium salt .
Benoxinate hydrochloride is represented by the following structural formula : [ MULTIMEDIA ] Chemical Name : 2 - ( Diethylamino ) ethyl 4 - amino - 3 - butoxybenzoate hydrochloride .
Each mL of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 0 . 3 % / 0 . 4 % contains : • • Active ingredients : fluorescein sodium 2 . 6 mg ( 0 . 3 % ) equivalent to fluorescein 2 . 3 mg ( 0 . 2 % ) , benoxinate hydrochloride 4 . 4 mg ( 0 . 4 % ) equivalent to benoxinate 3 . 9 mg ( 0 . 4 % ) • • Preservative : chlorobutanol 12 . 6 mg ( 1 . 3 % ) • • Inactive ingredients : povidone , hydrochloric acid , boric acid , water for injection .
Hydrochloric acid may be added to adjust pH ( 4 . 3 – 5 . 3 ) .
[ MULTIMEDIA ] [ MULTIMEDIA ] 12 CLINICAL PHARMACOLOGY 12 . 2 Pharmacodynamics Maximal corneal anesthesia usually occurs in about 5 - 45 seconds and lasts about 20 minutes after single administration .
The anesthetic effect may be extended by subsequent administration 10 - 20 minutes after the last administration .
13 NONCLINICAL TOXICOLOGY 13 . 1 Carcinogenesis , Mutagenesis , Impairment of Fertility Studies to evaluate the mutagenic or carcinogenic potential of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % have not been conducted .
Studies to evaluate impairment of fertility have not been conducted .
14 CLINICAL STUDIES Controlled clinical studies in adults and pediatric patients have demonstrated that topical administration of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % enables visualization and corneal anesthesia sufficient to enable applanation tonometry , tear fluid dynamics evaluation and short conjunctival and corneal procedures .
Maximal corneal anesthesia usually occurs in about 5 - 45 seconds and lasts about 20 minutes after single administration .
16 HOW SUPPLIED / STORAGE AND HANDLING Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution , 0 . 3 % / 0 . 4 % is supplied as a sterile , aqueous , topical ophthalmic solution with a fill volume of 5 mL in a 6 mL amber glass bottle and a black polypropylene cap with a sterilized rubber dropper bulb and glass pipette .
NDC 82260 - 734 - 05 Storage : Store in a refrigerator at 2 ° C to 8 ° C ( 36 ° F to 46 ° F ) .
Protect from light .
After opening , can be stored up to one month if stored at room temperature or until the expiration date on the bottle if stored in refrigerated conditions .
Keep tightly closed .
17 PATIENT COUNSELING INFORMATION Accidental Injury Precaution Advise patients not to touch their eyes for approximately 20 minutes after application .
Their eyes will be insensitive due to the effect of the anesthetic , and care should be taken to avoid accidental injuries .
Distributed by : Bausch & Lomb Americas Inc .
Bridgewater , NJ 08807 USA Manufactured by : Siegfried - Irvine Irvine , CA 92618 USA Patented .
See https : / / patents . bausch . com for US patent information .
© 2022 Bausch & Lomb Incorporated or its affiliates 9785200 PACKAGE / LABEL PRINCIPAL DISPLAY PANEL NDC 82260 - 734 - 05 Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 0 . 3 % / 0 . 4 % ( Sterile ) FOR TOPICAL OPHTHALMIC USE Rx only 5 mL BAUSCH + LOMB 97850000 [ MULTIMEDIA ] [ MULTIMEDIA ]
